ANDAORALTABLET
Approved
Aug 2005
Lifecycle
Post-LOE
Competitive Pressure
60/100
Mechanism of Action
[see Microbiology ()].
Indications (13)
the following infections in adultsskin structure infections • Urinary tract infections Limitations of Useindicating no beta-lactamase productionamoxicillinclavulanate potassium should not be useddevelopment of drug-resistant bacteriamaintain the effectiveness of amoxicillinclavulanate potassiumother antibacterial drugsclavulanate potassium should be used only to treatprevent infectionsstrongly suspected to be caused by susceptible bacteriastrongly suspected to be caused by bacteria